ESR1 and breast cancer: Our data therefore support the development of more effective SERDs or other novel ER-targeting mechanisms.27 The recent approval of elacestrant for ESR1-mutated metastatic BC represents an example; however, ESR1 mutations are rarely present at diagnosis.28